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Creutzfeldt-Jakob disease (CJD) is a fatal neurodegenerative disorder in which accumulation of the pathogenic prion 
protein induces neuronal damage and results in distinct pathologic features. This abnormal prion is an infectious 
protein and resistant to methods of sterilization currently being used. Therefore, management of definite, or 
suspected CJD patients requires additional precautions. We report our experience of a patient who had undergone 
brain biopsy for suspected of CJD. The patient was confirmed to have sporadic CJD.  (Korean J Anesthesiol 2011; 61: 
262-264)
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Creutzfeldt-Jakob disease (CJD) is a lethal form of dementia 
that causes progressive degeneration of the brain which in turn 
leads to death. It has a worldwide reported annual incidence 
of 1 per million [1]. CJD is classified as a form of transmissible 
spongiform encephalopathy (TSE) and the human forms of 
TSE are very rare. CJD is the most common form of human TSE. 
Major clinical problems are due to the small prions that enable 
them to reside in the microscopic crypt on instruments [2] and 
are resistant to all methods of sterilization currently in use, 
including autoclaving (121
oC for 15 min), high-dose ionizing 
radiation, and ultraviolet radiation [3]. CJD therefore has greatly 
increased the risk of potential cross-infection by surgical and 
anesthetic equipments. 
We report our anesthetic experience in a patient with CJD 
and discuss the anesthetic and surgical precautions of a patient 
with definite or probable CJD. 
Case Report 
A 64-year-old, 164 cm, 70 kg woman had a five-year history 
of hypertension and diabetes mellitus. She experienced in-
somnia, nausea, visual hallucination and left-side tingling 
sensation 4 months ago and memory impairment and gait 
disturbance became evident clinically 2 months ago. At that 
time, she underwent brain magnetic resonance imaging, which 
did not demonstrate abnormality. The patient presented with 
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generalized myoclonus, progressive gait disturbance, and 
deviation of the left eye 1 month ago. Clinically, her condition 
resembled that of terminal vegetative state. Brain MRI showed 
T2 hyperintensity of the right dominant cortex, caudate nucleus, 
putamen, and thalamus on diffusion-weighted sequences. 
Electroencephalogram showed nearly continuous high voltage 
1-1.5 Hz periodic sharp waves in the frontal area bilaterally. 
Under the suspicion of CJD the patient was admitted for brain 
biopsy.
The patient was scheduled last on the operating list. The 
operating room was cleared of unnecessary equipment and 
the wall of operating room was covered with vinyl chloride 
monomers. All staff members involved with the operation wore 
liquid-repellent gown, face-masks with plastic transparent 
shield visor, and double gloves (Fig. 1).
The mental status of the patient ranged from stupor to 
semicoma and vital signs were stable. Standard monitoring 
were applied before induction of anesthesia. Anesthesia 
was induced with a bolus injection of propofol 1.5 mg/kg in 
combination with remifentanil infusion at 0.5 μg/kg/min. 
Endotracheal intubation was facilitated by vecuronium 6 mg. 
Anesthesia was maintained with oxygen 5 L/min, propofol 50-
150 μg/kg/min, and remifentanil 0.05-0.1 μg/kg/min total 
intravenous anesthesia. Almost every equipment applied was 
of single-use nature, including face-masks, oropharyngeal 
airway, laryngoscopic blade, endotracheal tube, Ambu bag, 
O2 flowmeter, and stethoscope. The surgeon used hand-
drill instead of air-drill, and the entire surgical procedure 
took 40 minutes. Extubation was performed following in the 
operating room after gaining of spontaneous ventilation. The 
patient recovered in the operating room and was subsequently 
transferred to the private ward. All disposable equipment was 
destroyed and incinerated postoperatively.
Brain biopsy revealed neuronal loss, vaculoation, and astro-
cytosis in the brain tissue. Western blot demonstrated a mis-
folded, protease-resistant, pathogenic form of prion protein in 
the brain tissue. A diagnosis of sporadic CJD was made based 
on the above findings.
Discussion
CJD is a fatal degenerative disease of the central nervous 
system. It is one of the transmissible subacute spongiform 
encephalopathies. CJD is caused by infectious protein “prion” . 
Prion proteins are normal cellular proteins that have undergone 
a structural change rendering the abnormal protein resistant 
to degradation [4]. Sporadic CJD (sCJD) is the most common 
form and accounts for 85% of cases. It is a rapidly progressing 
illness with an onset of older age group and a median duration 
of four months. Iatrogenic CJD (iCJD) accounts for fewer than 
5% of cases. It is resulted from various types of therapeutic 
interventions including contaminated surgical equipment, 
corneal or dural transplants, or treatment with human-derived 
pituitary growth hormone [5]. In 1974, the first case of iCJD was 
reported in a 55-year-old woman whose symptoms began 18 
months after corneal transplant surgery [6]. We had an experi-
ence a case of iCJD in a 53-year-old woman whose symptoms 
began 23 years after brain tumor resection and dura mater 
grafting. In addition, deaths from CJD have been reported in 
neurosurgeon and pathologist [7,8]. In iatrogenic transmission, 
various latencies, from several months to several decades, 
have been reported. Variant CJD (vCJD) affects mainly young 
individuals with an average age of 29 years, and the median 
duration of illness is 14 months. A new aggressive human form, 
known as vCJD, was first descrided in the UK in 1996 [9].
Classification of CJD should be made between symptomatic 
and asymptomatic patients. Symptomatic patients are divided 
into those who have definite, probable or possible CJD, or 
vCJD [10]. Asymptomatic patients are those with no clinical 
symptoms, but are at risk of disease development due to family 
history or medical history (e.g. a history of previous dural graft). 
Definite diagnosis of CJD requires pathological confirmation, 
either at autopsy or from brain biopsy [4]. The histopathological 
background is spongy degeneration of the grey matter [1]. 
CJD is rare but due to their unusual resistance to standard 
decontamination methods and the consequent risk of patient-
patient transmission, management of the infected and, possibly 
infected patients requires additional precautions. In the 
most routine clinical contacts no additional precautions are 
Fig. 1. For the anesthetic and surgical management of the patients 
suspected of Creutzfeldt-Jakob disease, the operating room is cleared 
of unnecessary equipment and the wall of operating room is covered 
with vinyl chloride monomers. All the staff entering the operation 
wear liquid-repellent gown, face masks with plastic transparent 
shield visor, and double gloves.264 www.ekja.org
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required and isolation nursing is unnecessary. However, in the 
operationg room, controls are required to prevent iatrogenic 
transmission [10].
When a patient known to have, or suspected of having CJD is 
scheduled for anesthesia, special precaution is required thorough 
the procedure. The anesthesiologist should confirm the level of 
certainty of the diagnosis preoperatively. The operating room 
should be cleared of all unnecessary equipment, and staffing 
kept to minimum [2,11]. The patient should be scheduled last 
on the operating list where possible, to allow extended cleaning 
of room surfaces prior to its next use [10,12]. Staff must wear a 
disposable liquid-repellent gown over a plastic apron, gloves, 
mask and goggles or full-face visor for procedure [2,4]. These 
items should be used once only and destroyed by incineration. 
In asymptomatic at risk patients the above precautions also 
apply, but gowns may be reprocessed if not of single-use [4]. 
Invasive procedures, such as central venous cannulation and 
spinal anesthesia, mandate the use of full aseptic procedures 
including mask and eye protection [13].
Whenever possible, disposable anesthetic equipment 
should be used and incinerated afterward, which includes 
face-masks, oropharyngeal, nasal and laryngeal mask airway, 
laryngoscope, and tracheal tubes [2,4,13]. When non-single-use 
instruments are applied, they should be treated according to 
the patient’s and the tissue risk [10]. High risk tissues for CJD are 
those in brain, spinal cord, and posterior eye, and medium risk 
tissues are those in the anterior eye, olfactory epithelium and 
in vCJD lymphoid tissue. Instruments exposed to procedure 
involving these tissues should be destroyed in cases of definite 
or probable CJD. In remaining group of patients (those with 
possible infectivity), instruments exposed to procedures 
involving high and medium risk tissues should be quarantined 
until a definite diagnosis has been confirmed. Quarantined 
instruments may be used again for the same patient during the 
course of their treatment [4,13]. 
Farling and Smith [2] stated that ventilators must not be used 
again for other patients except those with a definitive diagnosis 
of CJD. In our case, we used Ambu-bags with TIVA, instead of 
anesthetic machines with vaporizers. However, this advice is not 
current. CJD Incidents Panel recommends that the anesthetic 
circuit should be disposed of, single-use filters should always be 
used and there is no requirement to quarantine the anesthetic 
machine [14]. It may be recommended to recover the patient in 
the operating room to avoid additional contamination. 
CJD is a rare disease and sporadic CJD is the most common. 
However, anesthesiologists should be aware of the nature of 
CJD and recommended precautions in handling of patients 
with CJD because it is potentially iatrogenically transmissible. 
This knowledge is necessary to provide optimal care for the 
patient and minimize the risk of transmission between hospital 
workers and patients. 
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